We are live on ! Find out more
DAWN

Day One Biopharmaceuticals
DAWN

Delisted

DAWN was delisted on the 22nd of April, 2026.

Back to rankings

164 hedge funds and large institutions have $1.19B invested in Day One Biopharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 62 increasing their positions, 39 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 39

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

3% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 33

1% less funds holding

Funds holding: 166 → 164 (-2)

7% less capital invested

Capital invested by funds: $1.28B → $1.19B (-$96M)

11.94% less ownership

Funds ownership: 104.89% → 92.95% (-12%)

38% less call options, than puts

Call options by funds: $2.08M | Put options by funds: $3.36M

Holders
164
Holders Change
-2
Holders Change %
-1.2%
% of All Funds
2.16%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
32
Increased
62
Reduced
39
Closed
33
Calls
$2.08M
Puts
$3.36M
Net Calls
-$1.27M
Net Calls Change
+$713K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$76.2M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$35M
3
BlackRock
BlackRock
New York
+$20.1M
4
Marshall Wace
Marshall Wace
United Kingdom
+$15.3M
5
ECM
Estuary Capital Management
Minnesota
+$13.5M

Top Sellers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
-$35.6M
2
MC
Maverick Capital
Texas
-$29.4M
3
RCM
RA Capital Management
Massachusetts
-$29.4M
4
Goldman Sachs
Goldman Sachs
New York
-$18.1M
5
VPC
Vestal Point Capital
New York
-$14.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
EC
26
EcoR1 Capital
California
$10.9M – – –
Adage Capital Partners
27
Adage Capital Partners
Massachusetts
$10.1M -$1.39M -100,000 -11%
WP
28
Woodline Partners
California
$10.1M +$22.2K +1,592 +0.2%
DCM
29
DAFNA Capital Management
California
$9.27M -$264K -19,000 -3%
Wellington Management Group
30
Wellington Management Group
Massachusetts
$9.27M +$135K +9,722 +1%
FLSM
31
Frazier Life Sciences Management
California
$8.74M – – –
Citadel Advisors
32
Citadel Advisors
Florida
$7.75M +$1.77M +127,052 +26%
Northern Trust
33
Northern Trust
Illinois
$6.93M +$723K +51,960 +10%
Charles Schwab
34
Charles Schwab
California
$6.78M +$390K +28,053 +6%
Goldman Sachs
35
Goldman Sachs
New York
$5.98M -$18.1M -1,302,068 -73%
Deutsche Bank
36
Deutsche Bank
Germany
$4.55M +$493K +35,460 +11%
SFM
37
Sphera Funds Management
Israel
$4.24M -$176K -12,640 -4%
PL
38
Parkwood LLC
Ohio
$3.48M +$3.83M +275,000 New
Two Sigma Investments
39
Two Sigma Investments
New York
$3.44M -$1.89M -135,725 -33%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$3.1M +$1.03M +74,091 +43%
Renaissance Technologies
41
Renaissance Technologies
New York
$3.09M +$2.07M +148,900 +157%
SCM
42
Stonepine Capital Management
Oregon
$2.98M +$408K +29,325 +14%
ECM
43
ExodusPoint Capital Management
New York
$2.73M +$2.99M +215,137 New
EIM
44
Essex Investment Management
Massachusetts
$2.63M +$325K +23,344 +13%
KCM
45
Kennedy Capital Management
Missouri
$2.46M +$64.2K +4,615 +2%
Millennium Management
46
Millennium Management
New York
$2.43M +$1.19M +85,606 +80%
PCH
47
Polar Capital Holdings
United Kingdom
$2.34M – – –
Qube Research & Technologies (QRT)
48
Qube Research & Technologies (QRT)
United Kingdom
$2.34M +$1.31M +94,468 +105%
BC
49
BIT Capital
Germany
$2.18M +$704K +50,626 +42%
Norges Bank
50
Norges Bank
Norway
$2.14M – – –
1
2
3 4 5

DAWN Hedge Fund Activity: Q4 2024 in Review

164 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q4 2024, worth a combined $1.19B — down 7.5% from $1.28B a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of DAWN and 32 opened new positions — a net loss of 1 holder — while 39 trimmed existing stakes and 62 added.

The largest buyer was Fidelity Investments, adding an estimated $76.2M. The largest seller was Viking Global Investors, exiting entirely with an estimated $35.6M sold.

  • 164 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q4 2024, down from 166 in Q3 2024.
  • Funds reported $1.19B of Day One Biopharmaceuticals stock for Q4 2024, down 7.5% quarter-over-quarter.
  • 32 funds opened new Day One Biopharmaceuticals positions in Q4 2024 and 33 closed out, a net change of -1 holder.
  • The largest Day One Biopharmaceuticals buyer in Q4 2024 was Fidelity Investments, an estimated $76.2M added.
  • The largest Day One Biopharmaceuticals seller in Q4 2024 was Viking Global Investors, an estimated $35.6M sold.

Based on aggregated 13F filings for Q4 2024.